Literature DB >> 10157897

In vitro properties of pressurized metered dose inhalers with and without spacer devices.

E Berg1.   

Abstract

Pressurized metered dose inhalers (pMDIs) have been used for the administration of drugs to patients with asthma since the late 1950s. However, it is only during the last few years that attention has been paid to how they work in detail. Studies have shown that the first dose, after the inhaler has been at rest for some hours, can be very variable. For suspension formulations, shaking the inhaler before actuation is important, since omitting shaking will affect the dose uniformity. The addition of a spacer device may increase the variability of the available dose. Factors affecting the available dose are, the electrostatic charge on the walls of the spacer device, the volume of the spacer device and the choice of material for the spacer device. Moreover, the fine particle dose, a measure of the effective deposition of inhaled drug in the airways, has been shown to be greater with a pMDI and a spacer device in comparison with a pMDI alone and is dependent on the choice of impactor inlet.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 10157897     DOI: 10.1089/jam.1995.8.suppl_3.s-3

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  10 in total

1.  Spacer devices increase dose of inhaled corticosteroids delivered.

Authors:  O J Dempsey; A M Wilson; B J Lipworth
Journal:  BMJ       Date:  1999-06-26

2.  The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellant-driven metered dose inhalers.

Authors:  Hugh D C Smyth; Vance P Beck; Dennis Williams; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2004-02-10       Impact factor: 3.246

3.  Aerosol profile extracted from spacers as a determinant of actual dose.

Authors:  Sylvia Verbanck; Chris Vervaet; Daniël Schuermans; Walter Vincken
Journal:  Pharm Res       Date:  2004-12       Impact factor: 4.200

Review 4.  In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review.

Authors:  Jolyon Mitchell; Steve Newman; Hak-Kim Chan
Journal:  AAPS PharmSciTech       Date:  2007-12-21       Impact factor: 3.246

5.  Early lung absorption profile of non-CFC salbutamol via small and large volume plastic spacer devices.

Authors:  B J Lipworth; D J Clark
Journal:  Br J Clin Pharmacol       Date:  1998-07       Impact factor: 4.335

6.  Adrenocortical activity with repeated twice daily dosing of fluticasone propionate and budesonide given via a large volume spacer to asthmatic school children.

Authors:  B J Lipworth; D J Clark; L C McFarlane
Journal:  Thorax       Date:  1997-08       Impact factor: 9.139

Review 7.  Safety of inhaled and intranasal corticosteroids: lessons for the new millennium.

Authors:  B J Lipworth; C M Jackson
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

8.  Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.

Authors:  Piotr Kuna; Mirco Govoni; Germano Lucci; Mario Scuri; Daniela Acerbi; Iwona Stelmach
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

9.  In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Pippa Hopkinson; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2009-02-09       Impact factor: 4.335

10.  Variability in Delivered Dose from Pressurized Metered-Dose Inhaler Formulations Due to a Delay Between Shake and Fire.

Authors:  Ross H M Hatley; Jacob Parker; John N Pritchard; Dirk von Hollen
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-09-16       Impact factor: 2.849

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.